Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 215 vs Bevacizumab in Chinese Advanced Non-Squamous NSCLC
NCT04466917Phase 3Withdrawn
- Sponsor
- Amgen
- Start
- May 2021
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Amgen. Planned start May 2021; status: withdrawn.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04466917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04466917.